Starting April 2012, we are doing Hepatitis C Antibody Testing! Who should be tested? http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm?s_cid=rr6104a1_w The cost is $25 (cash or check) and the results will be back within 24-48 business hours. All testing is confidential.
Takeda Pharmaceuticals is conducting a clinical research study evaluating people who have Crohn's disease. The purpose of this study is to learn more about the effectiveness and safety of vedolizumab subcutaneous (SC) injection compared to placebo SC injection in people with moderately to severely active Crohn's disease.
You must be Entyvio naive at screen and have an inadequate response or intolerance of Immunomodulators, Corticosteroids, or TNF-a antagonists.
Upon completion of this clinical research study, you may be eligible to participate in the vedolizumab Open Label Extension study.
For more information, call us at 918-513-3490.
Must be moderate to severe flare.
Can have been on a biologic in past, but stopped taking biologic due to financial reasons.
Inadequately responded to or are Intolerant to Conventional Therapies but Not Required to have Failed biologic therapy.
This is a JAK Inhibitor.
Must have inadequate response to Corticosteroids, Immunomodulators, TNFa Antagonists, Vedolizumab, or Ustekinumab.
Must be Moderate to Severe flare.
All types of IBS. Open label, single-arm, multi-center, interventional study in the US, to evaluate the potential of fuco-N-tetraose to support normal bowel habits in adults with IBS under "real world" conditions, 12 week treatment + monthly questionnaires.
Must have a current diagnosis of IBS and access to internet or smartphone to answer questionnaires.
This is a 12 week treatment with Fuco-N-Tetraose, registered with the FDA.
Placebo controlled study to evaluate the safety of a drug compared to placebo for induction and maintenance therapy with Moderate to severe UC.
This is a JAK Inhibitor, which is an oral compound.
Must have had an inadequate response to Corticosteroids, immunosuppresants, or biologic therapies.
Oral daily dosing for subjects with NASH Fibrosis, not cirrhosis. Fibroscan will be performed. 72 week treatment period and additional double-blind long term treatment for up to 3 additional years.
Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Cenicriviroc "CVC" for the treatment of liver Fibrosis (F2-F3) in adults with NASH.
Phase 2, multicenter, randomized, double-blind, placebo controlled proof of concept study to assess the efficacy of
Tradipitant in relieving symptoms of gastroparesis.
Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial of Emricasan, an Oral Caspase Inhibitor, in subject with Decompensated "NASH" Cirrhosis. 48 week treatment arm, BID oral dosing.
NO Liver Biopsies
History of variceal hemorrhage documented with endoscopy and/or history of moderate to severe ascites with diruetics.